**Listing of the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-21 (Canceled)

Claim 22 (Previously Presented) A purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens comprising a $V_H$ region having SEQ ID NO: 58 or a functional variant thereof and a $V_L$ region, wherein said functional variant of the $V_H$ region is SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 54, or SEQ ID NO: 62.

Claim 23. (Previously Presented) The polypeptide of claim 22, wherein the $V_L$ region is SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 48, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 60, or SEQ ID NO: 64.

Claim 24. (Canceled)

Claim 25. (Previously Presented) The polypeptide of claim 22, wherein the polypeptide is an antigen binding Fab fragment.

Claim 26. (Previously Presented) The polypeptide of claim 22, wherein the polypeptide is an immunoglobulin specific for a Rhesus D antigen.

Claim 27. (Presently Presented) The polypeptide of claim 26, wherein the immunoglobulin comprises at least one defined isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

Claim 28. (Previously Presented) A recombinant polynucleotide which encodes the polypeptide of claim 22.

Claim 29. (Previously Presented) A pharmaceutical composition comprising at least one polypeptide of claim 22.

Claim 30. (Previously Presented) A pharmaceutical composition comprising at least one immunoglobulin of claim 26.

Claim 31. (Previously Presented) A diagnostic composition for Rhesus D typing comprising at least one polypeptide of claim 22.

Claim 32. (Previously Presented) A diagnostic composition for Rhesus D typing comprising at least one immunoglobulin of claim 26.

Claim 33. (Previously Presented) A purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens comprising a $V_H$ region and a $V_L$ region having SEQ ID NO: 60 or a functional variant thereof, wherein said functional variant of the $V_L$ region is SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 48, SEQ ID NO: 52, SEQ ID NO: 56, or SEQ ID NO: 64.

Claim 34. (Previously Presented) The polypeptide of claim 33, wherein the $V_H$ region is SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 54, SEQ ID NO: 58, or SEQ ID NO: 62.

Claim 35. (Canceled)

Claim 36. (Previously Presented) The polypeptide of claim 33, wherein the polypeptide is an antigen binding Fab fragment.

Claim 37. (Previously Presented) The polypeptide of claim 33, wherein the polypeptide is an immunoglobulin specific for a Rhesus D antigen.

Claim 38. (Previously Presented) The polypeptide of claim 37, wherein the immunoglobulin comprises at least one defined isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

Claim 39. (Previously Presented) A recombinant polynucleotide which encodes the polypeptide of claim 33.

Claim 40. (Previously Presented) A pharmaceutical composition comprising at least one polypeptide of claim 33.

Claim 41. (Previously Presented) A pharmaceutical composition comprising at least one immunoglobulin of claim 37.

Claim 42. (Previously Presented) A diagnostic composition for Rhesus D typing comprising at least one polypeptide of claim 33.

Claim 43. (Previously Presented) A diagnostic composition for Rhesus D typing comprising at least one immunoglobulin of claim 37.

Claim 44. (Withdrawn) A method for preventing or treating a hematologic disorder in a subject comprising administering to the subject a pharmaceutical composition comprising at least one of the following

(a) a purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens comprising a $V_H$ region having SEQ ID NO: 58 or a functional variant thereof and a $V_L$ region;

(b) a purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens comprising a $V_H$ region and a $V_L$ region having SEQ ID NO: 60 or a functional variant thereof;

(c) an immunoglobulin specific for a Rhesus D antigen comprising a purified polypeptide having a $V_H$ region having SEQ ID NO: 58 or a functional variant thereof and a $V_L$ region;

(d) an immunoglobulin specific for a Rhesus D antigen comprising a purified polypeptide having a $V_H$ region and a $V_L$ region having SEQ ID NO: 60 or a functional variant thereof;

wherein the hematologic disorder is haemolytic disease of the newborn (HDN), immune thrombocytopenic purpura (ITP), or mistransfusion of Rhesus incompatible blood.